Co‐Delivery of aPD‐L1 and CD73 Inhibitor Using Calcium Phosphate Nanoparticles for Enhanced Melanoma Immunotherapy with Reduced Toxicity
Advanced Science · 2025-02 · 12 (7)
DOI: 10.1002/advs.202410545 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, online erschienen am 24.12.2024. Verfasst von Peng Liu und 11 weiteren Autor:innen. Beteiligte Einrichtung: Xiangya School of Pharmaceutical Sciences, Central South University, Changsha, Hunan, 410013, China. Hauptthemen laut MEDLINE: Calcium Phosphates, Nanoparticles, Melanoma, Immunotherapy. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key Research and Development Program of China, Key Program of National Natural Science Foundation of China, National Natural Science Foundation of China.
Abstract (Originalsprache)
Melanoma, a malignant skin tumor, presents significant treatment challenges, particularly in unresectable and metastatic cases. While immune checkpoint inhibitors (ICIs) targeting PD‐1/PD‐L1 have brought new hope, their efficacy is limited by low response rates and significant immune‐mediated adverse events (irAEs). Through multi‐omics data analysis, it is discovered that the spatial co‐localization of CD73 and PD‐L1 in melanoma correlates with improved progression‐free survival (PFS), suggesting a synergistic potential of their inhibitors. Building on these insights, a novel therapeutic strategy using calcium phosphate (CaP) nanoparticles is developed for the co‐delivery of aPD‐L1 and APCP, a CD73 inhibitor. These nanoparticles, constructed via a biomineralization method, exhibit high drug‐loading capacity and pH‐responsive drug release. Compared to free aPD‐L1, the CaP‐delivered aPD‐L1 effectively avoids systemic side effects while significantly enhancing anti‐tumor efficacy, surpassing even a 20‐fold dose of free aPD‐L1. Furthermore, the co‐delivery of aPD‐L1 and APCP via CaP nanoparticles demonstrates a synergistic anti‐tumor effect, with substantial immune activation and prevention of tumor recurrence through immune memory effects. These findings suggest that the co‐delivery of aPD‐L1 and APCP using CaP nanoparticles is a promising approach for improving melanoma immunotherapy, achieving enhanced efficacy and reduced toxicity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Xiangya School of Pharmaceutical Sciences, Central South University, Changsha, Hunan, 410013, China.
- Department of Nuclear Medicine, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, China.
- Key Laboratory of Biological Nanotechnology, Changsha, Hunan, 410008, China.
- Department of Dermatology, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, China.
- National Engineering Research Center of Personalized Diagnostic and Therapeutic Technology, Changsha, Hunan, 410008, China.
- Hunan Key Laboratory of Skin Cancer and Psoriasis, Changsha, Hunan, 410008, China.
ORCID-Profile: Wenhu Zhou
Förderung
- National Key Research and Development Program of China
- Key Program of National Natural Science Foundation of China
- National Natural Science Foundation of China
- Science Found for Creative Research Groups of the National Natural Science Foundation of China
- Science and Technology Innovation Program of Hunan Province
- Central South University Research Program of Advanced Interdisciplinary Studies
- China Postdoctoral Science Foundation
- Natural Science Foundation of Hunan Province in China
Zitieren
APA
Liu, P., Guo, J., Xie, Z., Pan, Y., Wei, B., Peng, Y., Hu, S., Ding, J., Chen, X., Su, J., Liu, H., & Zhou, W. (2025). Co‐Delivery of aPD‐L1 and CD73 Inhibitor Using Calcium Phosphate Nanoparticles for Enhanced Melanoma Immunotherapy with Reduced Toxicity. Advanced Science, 12(7). https://doi.org/10.1002/advs.202410545
Vancouver
Liu P, Guo J, Xie Z, Pan Y, Wei B, Peng Y, et al. Co‐Delivery of aPD‐L1 and CD73 Inhibitor Using Calcium Phosphate Nanoparticles for Enhanced Melanoma Immunotherapy with Reduced Toxicity. Advanced Science. 2025;12(7). doi:10.1002/advs.202410545
BibTeX
@article{Liu2025,
author = {Liu, Peng and Guo, Jia and Xie, Zuozhong and Pan, Yusheng and Wei, Benliang and Peng, Ying and Hu, Shuo and Ding, Jinsong and Chen, Xiang and Su, Juan and Liu, Hong and Zhou, Wenhu},
title = {Co‐Delivery of aPD‐L1 and CD73 Inhibitor Using Calcium Phosphate Nanoparticles for Enhanced Melanoma Immunotherapy with Reduced Toxicity},
journal = {Advanced Science},
year = {2025},
volume = {12},
number = {7},
doi = {10.1002/advs.202410545}
}
EUVIMED